Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with mild Alzheimer's disease. Results have be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• IONIS-MAPTRx

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Mild Alzheimer's Disease | Phase 1 | Status: COMPLETED | Results posted: 2025-04-08